Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU. V114 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as two additional serotypes (22F and 33F). Merck & Co is testing both an aluminum-adjuvanted and non-adjuvanted version of the vaccine.
V114’s (15-valent pneumococcal conjugate vaccine; Merck & Co) broader serotype coverage gives it significant market potential,
should it demonstrate broader immunogenicity to Prevnar 13 (13-valent pneumococcal conjugate vaccine; Pfizer) in Phase III studies.
If serotype shift occurs, V114 could replace Prevnar 13 on the market for adults aged 50 years and older due to its broader coverage
and greater diversity in serotypes.
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726